Application Note
*Optimal dilutions/concentrations should be determined by the researcher.
Application |
Recommended Dilution |
2 - 4 μg/ml |
1:10 - 1:500 |
1:10 - 1:500 |
1:10 - 1:500 |
1:10 - 1:500 |
1:100 - 1:2000 |
Not tested in other applications.
Product Note
This is specific for KSHV LANA2 (residues 143-310 epitope recognition).
Form
Liquid
Buffer
PBS
Preservative
0.1% Sodium azide
Storage
Store as concentrated solution. Centrifuge briefly prior to opening vial. For short-term storage (1-2 weeks), store at 4ºC. For long-term storage, aliquot and store at -20ºC or below. Avoid multiple freeze-thaw cycles.
Concentration
2 mg/ml (Please refer to the vial label for the specific concentration.)
Antigen Species
Kaposi's sarcoma-associated herpesvirus
Immunogen
Recombinant LANA2 fusion protein.
Purification
Protein G purified
Conjugation
Unconjugated
Note
For laboratory research use only. Not for any clinical, therapeutic, or diagnostic use in humans or animals. Not for animal or human consumption.
Purchasers shall not, and agree not to enable third parties to, analyze, copy, reverse engineer or otherwise attempt to determine the structure or sequence of the product.
Synonyms
Kaposi's sarcoma-associated herpesvirus LANA2 , HHV-8 LANA2 , Human herpesvirus 8 LANA2
Background
LANA2 (latency-associated nuclear antigen) is an inhibitor of p53-induced transcription in reporter assays and may be an apoptosis antagonist. It is a nuclear protein associated with Kaposi's sarcoma-associated herpes virus (KSHV), or human herpes virus 8. It is found in abundance in the nuclei of cultured cells from KSHV-infected hematopoietic tissues, such as PEL (primary effusion lymphoma) and CD (multicentric Castleman's disease). It does not appear to be expressed in KS (Kaposi's sarcoma) lesions.
Research Area